The injections of “Grindeks” original product Mildronate® will be manufactured in Russia

In concordance with the signed agreement, as of July 2008, the Russian JSC
FarmFirma Soteks has begun to manufacture the injection form of “Grindeks”
original product Mildronate®. 

JSC “Grindeks” Board Member, Director of the Final Dosage Forms Manufacturing
Lipmans Zeligmans emphasizes the importance of the agreement: „As a result of
the active, two-year-long cooperation, the manufacturing of injection form of
the leading original product Mildronate® from “Grindeks” will be launched also
in Russia, and this will make Mildronate® even more accessible to Russian
customers. We chose the manufacturing partner in Russia carefully and selected
a JSC FarmFirma Soteks. In comparison with other Russian enterprises, its
manufacturing infrastructure complies with the standards and technological
requirements of Good manufacturing practice, which is necessary for the
manufacturing of the Mildroate® injections. Our specialists have performed the
audit of the FarmFirma Soteks production unit, and, together with the
specialists from Farmfirma Soteks, have secured the introduction of
manufacturing technology. “ 

In concordance with the contracts signed before, the manufacturing of the
“Grindeks” injection forms will be continued by the pharmaceutical enterprise
Sanitas in Lithuania, and by the JSC Jelfa SA in Poland. 

“Grindeks” subsidiary Tallinn Pharmaceutical plant in Estonia specializes in
ointment manufacturing. In Latvia “Grindeks” manufactures tablets, capsules and
syrups. A considerable expansion of the infrastructure takes place now in
manufacturing plant in Latvia. After the plant will be audited in the autumn of
2008, the capacity of manufacturing will increase to 1.5 billion tablets and
500 million capsules per year. 

As informed before, within the framework of the agreement (fromFebruary 2008),
OJSC Farmstandart performs the exclusive sales and promotion of “Grindeks”
original product Mildronate® in the territory of Russian Federation, including
manufactured by FarmFirma Soteks. 

JSC “Grindeks” is the leading pharmaceutical company in the Baltic States. Its
main fields of action are: research, development and manufacturing of brand
products, generics and active pharmaceutical ingredients. “Grindeks”
specializes in the heart and cardiovascular, CNS and anti-cancer medication
therapeutic groups. 

A range of “Grindeks”'s products covers a successful combination of original
products and generics, with the original products Mildronate® and Ftorafur® and
more than 100 forms of effective and safe generics included therein. 

“Grindeks” concern consists of four subsidiary companies in Latvia, Estonia and
Russia, as well representatives and representative offices in fourteen
countries. Products of the company are exported to more than 40 countries and
its export comprises more than 96% of the total turnover. The main markets are:
the Baltic States, Russia and other CIS countries, Japan, USA. “Grindeks”
shares are listed in the Official List of Riga Stock Exchange. 

You are kindly invited to www.grindeks.lv to get to know more about our company!

Contacts:
Laila Klavina
Head of the Communications Department
JSC “Grindeks”
Phones: +371 67083370, + 371 29256012
e-mail: laila.klavina@grindeks.lv